Loading
Seattle paediatric neuro-oncologist who led COG ACNS0332, the trial that found adding carboplatin to radiotherapy improves survival in children with high-risk group 3 medulloblastoma but isotretinoin does not help.
Sarah Leary is a paediatric neuro-oncologist at Seattle Children's Hospital and a leader of the Children's Oncology Group brain tumour committee. She was first author of the 2021 JAMA Oncology report of ACNS0332, the randomised trial in high-risk medulloblastoma in which carboplatin given with radiotherapy improved event-free survival in group 3 tumours, while maintenance isotretinoin did not improve outcomes and was stopped early.
| Title | Journal | Year |
|---|---|---|
| ACNS0332: carboplatin during radiotherapy and isotretinoin maintenance in high-risk medulloblastoma | JAMA Oncology | 2021 |
Shares Childhood cancers (all types) and the tags paediatric, brain, trialist.
Shares Medulloblastoma, Childhood cancers (all types) and the tags paediatric, brain, trialist.
Shares Childhood cancers (all types) and the tags paediatric, brain, trialist.
Shares the tags brain, trialist.
Shares the tags brain, trialist.
Shares the tags brain, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.